GlobeNewswire

New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio

Share
  • EVRYSDI 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy (SMA)
  • OCREVUS data show its consistent benefit on slowing disease progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS)
  • Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) reinforce safety and efficacy, including in patients with concomitant autoimmune diseases (CAIDs)
  • Data for investigational MS medicine fenebrutinib support its safety profile and high potency
  • Additional presentations on investigational programmes, including Alzheimer’s disease and Huntington’s disease, help advance scientific understanding of neurological disorders


Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Roche neuroscience portfolio across six therapeutic areas, including EVRYSDI™ (risdiplam) for spinal muscular atrophy (SMA), OCREVUS® (ocrelizumab) in relapsing and primary progressive multiple sclerosis (RMS and PPMS), investigational Bruton’s tyrosine kinase inhibitor (BTKi) fenebrutinib in Phase III trials for RMS and PPMS, ENSPRYNG® (satralizumab) in neuromyelitis optica spectrum disorder (NMOSD), and data from investigational programmes in Alzheimer’s disease (AD) and Huntington’s disease (HD).

“Following U.S. FDA and global approvals for our groundbreaking therapies in SMA and NMOSD, Roche’s data at AAN reflect our continued commitment to meaningful therapeutic progress for people living with neurological disorders,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We are proud to collaborate with patient advocates, academia, industry and the broader healthcare community through cutting-edge research and partnerships to advance the scientific understanding of neurological conditions, which have historically been among the hardest disorders to study, diagnose and treat.”

Spinal Muscular Atrophy (SMA)
Roche will present data from five studies from the EVRYSDI clinical development programme, which was designed to represent a broad spectrum of people living with SMA. The programme includes infants aged 2 months to adults aged 60 years with varying degrees of disability, including people with scoliosis or joint contractures, and those previously treated for SMA with another medication.

New 2-year findings from Part 2 of the Phase II/III FIREFISH trial show longer-term efficacy and safety of EVRYSDI in infants with symptomatic Type 1 SMA treated with EVRYSDI. This includes the number of infants able to sit without support for 5 and 30 seconds, a key motor milestone not normally seen in the natural course of the disease, as well as data on event-free survival and reduced hospitalisations.

Additional data being presented across EVRYSDI’s broad clinical trial programme include updated data from the JEWELFISH trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of EVRYSDI in patients previously treated with SMA targeting therapies, as well as updated pooled safety analyses from the FIREFISH, SUNFISH, RAINBOWFISH and JEWELFISH trials.

Multiple Sclerosis (MS)
Roche will be presenting data from its MS Franchise, including five presentations covering OCREVUS and results from studies on the investigational BTKi fenebrutinib. Real-world data continue to show the highest persistence and adherence to OCREVUS, the only MS therapy with a twice-yearly dosing schedule, over one year compared to other disease-modifying therapies (DMTs). Additionally, a post-hoc analysis of the ORATORIO Phase III PPMS study will be presented, which suggest OCREVUS significantly slowed atrophied T2-lesion volume accumulation, a subclinical measure of disease progression. Furthermore, interim analysis of the open-label Phase IIIb ENSEMBLE study shows OCREVUS treatment provided consistent benefit over one year in patients who were recently diagnosed with relapsing-remitting multiple sclerosis (RRMS) and had not received prior DMT.

Roche is continuing to advance the science in MS and is exploring the investigational medicine fenebrutinib. Data from fenebrutinib, a highly selective, non-covalent, reversible oral BTKi, support its safety profile in several autoimmune diseases and high potency, which is encouraging for the ongoing Phase III studies in RMS and PPMS. Fenebrutinib is a dual inhibitor of both B-cell and myeloid lineage-cell activation, which may offer a novel approach to slowing disease progression by targeting both acute and chronic inflammatory aspects of MS.

Neuromyelitis Optica Spectrum Disorder (NMOSD)
Roche will present five sets of data on adults living with NMOSD. Data from the Phase III SAkuraStar and SAkuraSky clinical trials reinforce the favourable safety and efficacy of this therapy for those living with NMOSD, including patients with concomitant autoimmune diseases (CAIDs).

New longitudinal, observational data from the CIRCLES study, conducted in collaboration with the Guthy-Jackson Charitable Foundation, a patient advocacy organisation dedicated to funding research on NMOSD epidemiology, pathogenesis and treatment, will also be presented. The CIRCLES study explored factors that influence treatment change in people living with NMOSD, including those who have experienced only one relapse.

Alzheimer’s Disease (AD)
Roche will present data on the increased use of home nursing capabilities in the Phase III GRADUATE studies of gantenerumab during the COVID-19 pandemic, which enabled home-bound trial participants to continue dosing to maintain medicine exposure.

Gantenerumab is a late-stage investigational anti-beta-amyloid antibody being evaluated in two Phase III studies (GRADUATE I and II), which are the only late-stage AD clinical trials to offer subcutaneous administration. We expect data from the studies in 2022.

Huntington’s Disease (HD)
Roche will also present an analysis of the Enroll-HD study and REGISTRY database, which will highlight the role that genetic factors and medical history may have in predicting the rate of disease progression in HD. These data may help advance the understanding of HD and inform future treatment approaches for this rare, neurological condition.

The full range of data from Roche’s clinical development programme in neuroscience being presented at 2021 AAN include:

Medicine and/or Therapeutic Area Abstract Title

Presentation Number (type), Session Title
Presentation Date
Time
EVRYSDI
(risdiplam)
for Spinal Muscular Atrophy
FIREFISH Part 2: 24-month Efficacy and Safety of Risdiplam in Infants with Type 1 Spinal Muscular Atrophy (SMA) P6.062
P6: Neuromuscular Disorders and Clinical Trials
SUNFISH Part 2: 24-month Efficacy and Safety of Risdiplam in Patients with Type 2 or Non-ambulant Type 3 Spinal Muscular Atrophy (SMA) P6.060
P6: Neuromuscular Disorders and Clinical Trials
JEWELFISH: Safety and Pharmacodynamic Data in Non-naïve Patients with Spinal Muscular Atrophy (SMA) Receiving Treatment with Risdiplam P6.064
P6: Neuromuscular Disorders and Clinical Trials
Pooled Safety Data from the Risdiplam Clinical Trial Development Program P6.067
P6: Neuromuscular Disorders and Clinical Trials
RAINBOWFISH: A study of Risdiplam in Newborns with Presymptomatic Spinal Muscular Atrophy (SMA) P6.076
P6: Neuromuscular Disorders and Clinical Trials 2
OCREVUS (ocrelizumab) for Multiple Sclerosis  B-Cell Subset Depletion Following Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis P15.206
P15: MS Therapeutics MOA and Safety   
Evolution of Lesions that Shrink or Disappear into Cerebrospinal Fluid (Atrophied T2 Lesion Volume) in Primary-Progressive Multiple Sclerosis: Results from the Phase III ORATORIO Study P15.151
P15: MS Neuroimaging  
Recently Diagnosed Early-Stage RRMS: NEDA, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data from the Ocrelizumab Phase IIIb ENSEMBLE Study P15.099
P15: MS Clinical Trials and Therapeutics   
Adherence and Persistence to Disease-modifying Therapies for Multiple Sclerosis and Their Impact on Clinical and Economic Outcomes in a U.S. Claims Database P15.228
P15: MS Health Care System/Policy Based Research  
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis P15.203 
P15: MS Therapeutics MOA and Safety 
Fenebrutinib for Multiple Sclerosis The Safety of Fenebrutinib in a Large Population of Patients with Diverse Autoimmune Indications Supports Investigation in Multiple Sclerosis (MS)



S25.005 (oral presentation)
S25: MS and CNS Inflammatory Disease: Emerging Therapeutics and Biomarkers 
Tuesday, April 20 at 4:40 pm ET
Fenebrutinib Demonstrates the Highest Potency of Bruton Tyrosine Kinase Inhibitors (BTKis) in Phase 3 Clinical Development for Multiple Sclerosis (MS) P15.091
P15: MS Clinical Trials and Therapeutics  
ENSPRYNG (satralizumab) for Neuromyelitis Optica Spectrum Disorder

Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder and Concomitant Autoimmune Disease

P2.019 
P2: Autoimmune Neurology: Advances in Neuromyelitis Optica Spectrum Disorder (NMOSD) 
Neuromyelitis Optica Spectrum Disorder Disease Phenotype Correlates with Treatment Change in NMOSD Patients of the CIRCLES Cohort



P2.091
P2: Autoimmune Neurology: Clinical Observations and Advances 
Demographic and Relapse Correlates of Treatment Change in NMOSD Patients: Analysis of the CIRCLES Study

P2.013
P2: Autoimmune Neurology: Advances in Neuromyelitis Optica Spectrum Disorder (NMOSD) 
Relapse Profile Correlates with Treatment Change in NMOSD Patients of the CIRCLES Cohort



P2.012
P2: Autoimmune Neurology: Advances in Neuromyelitis Optica Spectrum Disorder (NMOSD) 
Correlates of Rituximab Discontinuation in Patients with NMOSD: a CIRCLES Cohort Analysis



P2.014 
P2: Autoimmune Neurology: Advances in Neuromyelitis Optica Spectrum Disorder (NMOSD) 
Alzheimer’s Disease Linking Amyloid to Cognition in the Pathogenesis and Treatment of Alzheimer’s Disease: Toward the Development of a “Quantitative A/T/N Model” P1.052
P1: Aging and Dementia: Biomarkers
Gantenerumab for Alzheimer’s Disease Utilization of Home Nursing to Mitigate the Impact of COVID-19 on the Conduct of the Gantenerumab GRADUATE Trials P1.014
P1: Aging and Dementia: Clinical Trials
Semorinemab for Alzheimer’s Disease A Disease Progression Model for Alzheimer’s Disease Predicts Longitudinal Trajectory of CDR-SB Score Across Different Stages of the Disease P1.061
P1: Aging and Dementia: Neuropsychology
Huntington’s Disease Burden of Illness among U.S. Medicare Beneficiaries with Late-onset Huntington’s Disease  P14.043
P14: Huntington’s Disease

Clinical Characteristics of Late-Onset Huntington’s Disease in North Americans from the Enroll-HD Study P14.046
P14: Huntington’s Disease

Clustering and Prediction of Disease Progression Trajectories in Huntington’s Disease: An Analysis of the Enroll-HD and REGISTRY Database Using a Machine Learning Approach P14.147
P14: Clinical Trials, Surveys, and Studies in Movement Disorders

About EVRYSDI™ (risdiplam)
EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier designed to treat SMA by increasing production of the survival of motor neuron (SMN) protein. SMN protein is found throughout the body and is critical for maintaining healthy motor neurons and movement. EVRYSDI is administered daily at home in liquid form by mouth or by feeding tube.

The U.S. Food and Drug Administration (FDA) approved EVRYSDI for the treatment of SMA in adults and children 2 months of age and older. EVRYSDI was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and 2019, respectively. At this time, EVRYSDI has been approved in 38 countries and submitted in a further 33 countries.

About OCREVUS® (ocrelizumab)
OCREVUS is the first and only therapy approved for both RMS (including clinically isolated syndrome, RRMS and active, or relapsing, SPMS) and PPMS, with dosing every six months. OCREVUS is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. This nerve cell damage can lead to disability in people with MS. Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved.

OCREVUS is administered by intravenous infusion every six months. The initial dose is given as two 300 mg infusions given two weeks apart. Subsequent doses are given as single 600 mg infusions. With rapidly growing real-world experience and more than 200,000 people treated globally, OCREVUS is the first and only therapy approved for relapsing MS (RMS; including RRMS and active, or relapsing, secondary progressive MS [SPMS], in addition to clinically isolated syndrome [CIS] in the U.S.) and PPMS. At Roche, we are constantly striving to optimise the care for people with MS and a shorter two-hour OCREVUS infusion time, dosed twice yearly (six-monthly), is now approved for eligible people with RMS or PPMS in the U.S and EU.

OCREVUS is approved in 95 countries across North America, South America, the Middle East, Eastern Europe, as well as in Australia, Switzerland, the United Kingdom and the European Union (EU).

About ENSPRYNG® (satralizumab)
ENSPRYNG, which was designed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that targets interleukin-6 (IL-6) receptor activity. The cytokine IL-6 is believed to be a key driver in NMOSD, triggering the inflammation cascade and leading to damage and disability. ENSPRYNG was designed using novel recycling antibody technology which, compared to conventional technology, allows for longer duration of the antibody and subcutaneous dosing every four weeks. 

Positive Phase III results for ENSPRYNG, as both monotherapy and in combination with baseline immunosuppressive therapy, suggest that IL-6 inhibition is an effective therapeutic approach for NMOSD. The Phase III clinical development programme for ENSPRYNG includes two studies: SAkuraStar and SAkuraSky. 

ENSPRYNG is currently approved in 18 countries, including the United States, Canada, Japan and Switzerland. Applications are under review with numerous regulators. 

ENSPRYNG has been designated as an orphan drug in the U.S., Europe and Japan.

About Roche in Neuroscience
Neuroscience is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.

Roche is investigating more than a dozen medicines for neurological disorders, including spinal muscular atrophy, multiple sclerosis, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, Duchenne muscular dystrophy and autism spectrum disorder. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Minion 9, single
[2] No reference linking within document please!
[3] Lorem ipsum

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17

Patrick Barth
Phone: +41 61 688 44 86
Dr. Daniel Grotzky
Phone: +41 61 688 31 10

Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74

Nathalie Meetz
Phone: +41 61 687 43 05
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67


Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Dr. Lisa Tuomi
Phone: +1 650 467 8737
e-mail: tuomi.lisa@gene.com

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

NEP’s Solution for Aurora, North One and Extreme E Tests Its Metal In Some of the World’s Harshest Conditions13.4.2021 19:21:56 CEST | Press release

SHOWCASING CUTTING EDGE TECHNOLOGY & SUSTAINABILITY WORKING TOGETHER LONDON, April 13, 2021 (GLOBE NEWSWIRE) -- Last weekend marked the first event for Extreme E, a new all-electric off-road racing series designed to highlight the climate crisis. NEP Group, the leading technical partner for content producers around the globe, worked with Extreme E and host broadcaster Aurora Media Worldwide and North One, to create a cutting-edge, sustainable broadcast solution that brought the first race, in AlUla, Saudi Arabia, into homes in 180 countries around the globe. Designed to mirror Extreme E’s goals of marrying the latest technology with sustainability and building solutions to meet the rigors of the world’s harshest conditions, NEP’s innovative broadcast services will be used by Aurora and North One at races in Senegal, Greenland, Brazil and Patagonia as the series continues. NEP’s complete end-to-end broadcast package includes a custom IP flypack, remote production solutions, crewing, sat

Annual General Meeting 2021: Tecan shareholders endorse all motions proposed by the Board of Directors13.4.2021 17:45:00 CEST | Press release

Votes cast exclusively through the independent proxy in line with COVID-19 Ordinance 3 of the Swiss government to combat the pandemicIncrease in the dividend from CHF 2.20 to CHF 2.30 per share Lukas Braunschweiler, Heinrich Fischer, Oliver Fetzer, Karen Huebscher, Christa Kreuzburg and Daniel R. Marshak re-elected as members of the Board of DirectorsLukas Braunschweiler confirmed by shareholders as Chairman of the BoardChrista Kreuzburg, Oliver Fetzer and Daniel R. Marshak confirmed as members of the Compensation CommitteeAll proposals relating to compensation approved Männedorf, Switzerland, April 13, 2021 – The Annual General Meeting of the Tecan Group (SIX Swiss Exchange: TECN) endorsed all motions proposed by the Board of Directors on April 13, 2021. The Annual General Meeting was held at the headquarters of the company, without personal attendance by shareholders. Voting rights could only be exercised through the independent proxy in line with the Federal Act on the Statutory Pri

Stockwik offentliggör avsikt att genomföra en riktad nyemission om upp till 1 026 055 nya aktier13.4.2021 17:31:00 CEST | Pressemelding

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDANT OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION INTE SKULLE VARA FÖRENLIG MED TILLÄMPLIGA FÖRESKRIFTER ELLER KRÄVA REGISTRERING ELLER LIKNANDE ÅTGÄRDER. VÄNLIGEN SE VIKTIG INFORMATION I SLUTET AV PRESSMEDDELANDET. Stockwik Förvaltning AB (publ) (”Stockwik” eller ”Bolaget”) offentliggör avsikt att genomföra en riktad nyemission om upp till 1 026 055 nya aktier till svenska och internationella institutionella investerare (den ”Riktade Nyemissionen”). Bolaget avser att genomföra den Riktade Nyemissionen med avvikelse från aktieägarnas företrädesrätt med stöd av bemyndigandet från årsstämman den 8 maj 2020. Stockwik har gett Pareto Securities AB (”Pareto Securities”) i uppdrag att utreda förutsättningarna för att genomföra den Riktade Nyemissionen genom

Stockwik announces intention to carry out a directed new share issue of up to 1,026,055 new shares13.4.2021 17:31:00 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Stockwik Förvaltning AB (publ) (”Stockwik” or the ”Company”) hereby announces intention to carry out a directed new share issue of up to 1,026,055 new shares directed to Swedish and international institutional investors (the “Directed New Share Issue”). The Company intends to carry out the Directed New Share Issue with deviation from the shareholders' preferential rights pursuant to the authorization granted by the annual general meeting on 8 May 2020. Stockwik has engaged Pareto Securities AB (“Pareto Securities”) to investigate the conditions to carry out the Directed New Shar

Norsk Hydro: Innkalling til generalforsamling 202113.4.2021 16:27:22 CEST | Pressemelding

Aksjeeierne i Norsk Hydro ASA innkalles til ordinær Generalforsamling torsdag 6. mai 2021 kl. 10:00. Generalforsamlingen vil i år gjennomføres digitalt med elektronisk stemmegivning som følge av Covid-19 situasjonen. Se vedlagt guide for online deltakelse. Det er også mulig å forhåndsstemme eller gi fullmakt før møtet. Fullstendig innkalling, agenda og vedlegg er vedlagt. Alle relevante dokumenter ligger på www.hydro.com/generalforsamling Investorkontakt Line Haugetraa +47 41406376 Line.haugetraa@hydro.com Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg Arsberetning og arsregnskap 2020Guide for digital deltakelseHydros lonnspolitikkInnkalling til ordinaer generalforsamling 2021Innstilling fra Valgkomiteen 2021Moteseddel

Norsk Hydro: Notice of Annual General Meeting 202113.4.2021 16:27:22 CEST | Press release

Notice is given that the Annual General Meeting of Norsk Hydro ASA will be held on Thursday 6 May 2021 at 10:00 (CEST). Please be informed that the Annual General Meeting will be held as a digital meeting with electronic voting due to the Covid-19 situation. Please refer to the attached guide for online participation. It is also possible to vote in advance or attend the meeting by proxy. The full notice, agenda and appendices are attached. All relevant documents can be found on www.hydro.com/generalmeeting Investor contact: Line Haugetraa +47 41406376 Line.haugetraa@hydro.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments Financial Statements and Board of Directors report 2020Guideline for online participationHydro remuneration policyNotice of General Meeting 2021Recommendation from the Nomination Committee 2021Voting instructions

Kallelse till årsstämma i Stockwik Förvaltning AB (publ)13.4.2021 16:00:00 CEST | Pressemelding

Aktieägarna i Stockwik Förvaltning AB (publ), org. nr 556294-7845, kallas härmed till årsstämma fredagen den 14 maj 2021 kl. 10:00. Mot bakgrund av risken för spridning av Covid-19 och myndigheternas föreskrifter och råd om undvikande av sammankomster har styrelsen med stöd av tillfälliga lagregler beslutat att årsstämman ska genomföras utan fysisk närvaro genom att aktieägare utövar sin rösträtt endast genom poströstning. FÖRUTSÄTTNINGAR FÖR DELTAGANDE Den som önskar att genom poströstning delta i årsstämman ska dels vara upptagen i den av Euroclear Sweden AB framställda aktieboken per onsdagen den 5 maj 2021, dels ha anmält sitt deltagande genom att avge sin poströst i enlighet med anvisning under rubriken POSTRÖSTNING nedan så att poströsten är bolaget tillhanda senast onsdagen den 12 maj 2021. För att ha rätt att delta i årsstämman måste en aktieägare som låtit förvaltarregistrera sina aktier, förutom att anmäla sig till årsstämman genom att avge sin poströst, låta registrera aktie